Erasca Prices Upsized $550M Stock Offering at $17.50, a 9% Discount
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca priced a substantially upsized follow-on offering of 31.4 million shares at $17.50, a 9% discount to the last close of $19.26, raising $550 million before the greenshoe. Net proceeds are expected to be ~$516 million, with up to ~$593.5 million if underwriters fully exercise the overallotment. The deal is set to close July 15, 2026. This follows the July 13 shelf filing and comes amid a volatile period for the stock, which has faced a patient death disclosure, a patent dispute, and a securities class action lawsuit. The offering is highly dilutive—representing roughly 10% of shares outstanding—and the discount signals weak demand, likely pressuring the stock further. Proceeds are earmarked for R&D and general corporate purposes, extending the cash runway as the company advances its lead asset ERAS-0015.
At the time of this announcement, ERAS was trading at $19.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $1.33 to $24.28. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.